Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A5 | Q9Y345 | 2/20 | 0.85 |
| ▸ | NOD1 | Q9Y239 | 13/20 | 0.75 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.58 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.58 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.55 |
| ▸ | FAAH | O00519 | 1/20 | 0.55 |
| ▸ | DNM1 | Q05193 | 1/20 | 0.54 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1245563 | 1.00 | SLC6A5 (0.85) | SLC6A5NOD1ITGB3ITGA2BFOLH1 | |
| SCHEMBL4020128 | 1.00 | SLC6A5 (0.85) | SLC6A5NOD1ITGB3ITGA2BFOLH1 | |
| SCHEMBL9716739 | 1.00 | SLC6A5 (0.85) | SLC6A5NOD1ITGB3ITGA2BFOLH1 | |
| SCHEMBL343693 | 1.00 | SLC6A5 (0.85) | SLC6A5NOD1ITGB3ITGA2BFOLH1 | |
| SCHEMBL11213737 | 1.00 | SLC6A5 (0.85) | SLC6A5NOD1ITGB3ITGA2BFOLH1 | |
| SCHEMBL337703 | 1.00 | SLC6A5 (0.85) | SLC6A5NOD1ITGB3ITGA2BFOLH1 | |
| SCHEMBL9716743 | 1.00 | SLC6A5 (0.85) | SLC6A5NOD1ITGB3ITGA2BFOLH1 | |
| SCHEMBL9635202 | 1.00 | SLC6A5 (0.85) | SLC6A5NOD1ITGB3ITGA2BFOLH1 | |
| SCHEMBL15475 | 1.00 | SLC6A5 (0.85) | SLC6A5NOD1ITGB3ITGA2BFOLH1 | |
| SCHEMBL1487710 | 1.00 | SLC6A5 (0.85) | SLC6A5NOD1ITGB3ITGA2BFOLH1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10195127-B2 | Cosmetic composition | AJINOMOTO CO., INC. (JP) | 2019-02-05 | — | — | US | claimed |
| JP-6192034-A | — | — | None | — | — | JP | disclosed |
| JP-1242517-A | — | — | None | — | — | JP | disclosed |
| US-20250082560-A1 | PARTICLES AND USE THEREOF | MATSUMOTO YUSHI-SEIYAKU CO., LTD. (JP) | 2025-03-13 | — | — | US | disclosed |
| EP-4442736-A1 | PARTICLES AND USE THEREOF | Matsumoto Yushi-Seiyaku Co., Ltd. (JP) | 2024-10-09 | — | — | EP | disclosed |
| WO-2023139987-A1 | PARTICLES AND USE THEREOF | 松本油脂製薬株式会社 | 2023-07-27 | — | — | WO | disclosed |
| CN-112251473-B | Preparation of N by using microreactorεMethod for producing-lysine-based surfactant | 南京先进生物材料与过程装备研究院有限公司 | 2022-07-22 | — | — | CN | disclosed |
| CN-114423445-A | Treatment of neurological diseases using complement inhibitors | RA制药公司 | 2022-04-29 | — | — | CN | disclosed |
| CN-113966224-A | Treatment of inflammatory diseases with complement inhibitors | RA制药公司 | 2022-01-21 | — | — | CN | disclosed |
| CN-112251473-A | Preparation of N by using microreactorεMethod for producing-lysine-based surfactant | 南京先进生物材料与过程装备研究院有限公司 | 2021-01-22 | — | — | CN | disclosed |
| US-10195127-B2 | Cosmetic composition | AJINOMOTO CO., INC. (JP) | 2019-02-05 | — | — | US | disclosed |
| US-20160000676-A1 | COSMETIC COMPOSITION | AJINOMOTO CO., INC. (JP) | 2016-01-07 | — | — | US | disclosed |
| US-6869930-B1 | Acylated insulin | NOVO NORDISK A/S (DK) | 2005-03-22 | — | — | US | disclosed |
| JP-H06192034-A | COSMETIC | KAO CORP | 1994-07-12 | — | — | JP | disclosed |
| EP-0473700-A1 | AN ENZYME-CATALYZED PROCESS FOR PREPARING N-ACYL AMINO ACIDS AND N-ACYL AMINO ACID AMIDES | NOVO NORDISK A/S (DK) | 1992-03-11 | — | — | EP | disclosed |
| EP-0178911-B1 | COMPOSITION CONTAINING A PENEM OR CARBAPENEM ANTIBIOTIC | SANKYO COMPANY LIMITED (JP) | 1992-01-22 | — | — | EP | disclosed |
| WO-1990014429-A1 | AN ENZYME-CATALYZED PROCESS FOR PREPARING N-ACYL AMINO ACIDS AND N-ACYL AMINO ACID AMIDES | NOVO NORDISK A/S (DK) | 1990-11-29 | — | — | WO | disclosed |
| JP-H01242517-A | HAIR COSMETIC COMPOSITION | AJINOMOTO CO INC | 1989-09-27 | — | — | JP | disclosed |
| US-4757066-A | Reduces renal toxicity | SANKYO COMPANY LIMITED (JP) | 1988-07-12 | — | — | US | disclosed |
| EP-0178911-A2 | Composition containing a penem or carbapenem antibiotic | SANKYO COMPANY LIMITED (JP) | 1986-04-23 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160000676-A1 | COSMETIC COMPOSITION | CUTA, H1-0, AADAT | SLC6A5 2031/4885NOD1 4769/4885ITGB3 2883/4885 |
| US-10195127-B2 | Cosmetic composition | CUTA, H1-0, AADAT | SLC6A5 2031/4885NOD1 4769/4885ITGB3 2883/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.